Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
- ID
- 47372
- Status
- summarized
- Published
- 17 Nov 2026, 10:50 PM
- Fetched
- 18 Nov 2026, 1:46 AM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 3.0
- Created
- 18 Nov 2026, 1:47 AM
- Tags
- Audience
- ai_ml_learnerssaas_founders
What happened
Isomorphic Labs raised a $5B Series C co-led by Greenoaks and Sequoia, with Andreessen Horowitz joining and existing investors including Alphabet’s GV and CapitalG, Thrive, MGX, Temasek, and the UK Sovereign AI Fund. The DeepMind spinout says its AI drug-design engine has produced positive preclinical results in oncology and immunology, and it has deals with Eli Lilly, Novartis, and Johnson & Johnson; the round follows a $2.1B Series B in May and will fund the engine plus expansion into more medicine types. Isomorphic did not disclose a valuation, though Bloomberg reported it was seeking a $50B valuation; Demis Hassabis left the DeepMind CEO role to focus on drug discovery and became DeepMind chairman, after sharing the Nobel Prize in chemistry with John Jumper for AlphaFold.
Why it matters
For most developers and SaaS founders, this is a biotech funding story with no direct tooling, API, or platform change to adopt; the concrete signal is that AlphaFold-derived commercial work is being capitalized at biotech scale ($5B round, reported $50B valuation target) and validated through pharma partnerships and preclinical results, not through a developer product. AI/ML learners should treat it as a long-horizon research-commercialization data point, not a reason to pivot into drug discovery, and local SaaS founders should not read it as a shift in Malaysian startup conditions.
Discussion angle
Isomorphic’s $5B round shows that some AI applications need pharma-scale capital and years of preclinical validation; compare that with developer-facing AI tools that ship weekly—where should local AI/ML learners spend their time if they want faster feedback loops?